FINWIRES · TerminalLIVE
FINWIRES

$UTHR

67 stories mentioning UTHRUpdated 3h ago

Every FINWIRES story that references UTHR, newest first.

Insider Trading

United Therapeutics Insider Sold Shares Worth $4,962,488, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 29, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,962,488. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000109/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,003,976, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 28, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,003,976. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000108/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,038,971, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 27, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,038,971. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000107/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,051,519, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 24, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,051,519. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000106/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,040,380, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 22, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,040,380. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 748,828 common shares of the company, with 40,513 shares held directly and 708,315 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000104/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,056,298, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 21, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,056,298. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000103/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,101,939, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 17, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,101,939. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000101/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,091,949, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 13, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,091,949. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000097/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,173,660, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 10, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,173,660. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000096/xslF345X05/primarydocument.xml

$UTHR
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Wire

BofA Securities Adjusts United Therapeutics Price Target to $613 From $620

United Therapeutics (UTHR) has an average rating of overweight and mean price target of $677.33, according to analysts polled by FactSet.Price: $542.20, Change: $-10.28, Percent Change: -1.86%

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,235,756, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on July 09, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,235,756. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000095/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,255,111, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 08, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,255,111. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000094/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,309,296, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 07, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,309,296. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000093/xslF345X05/primarydocument.xml

$UTHR
Wire

United Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says

United Therapeutics' (UTHR) pursuit of the idiopathic pulmonary fibrosis market is "the more important debate" as the IPF peak opportunity could be about twice the size of the current revenue base, UBS said in a note Monday.The brokerage said it expects the company to file for Tyvaso in IPF by the end of summer and believes investors looking for a "dip" in the company's valuation on the impact to base business "could be disappointed."For Q2, UBS expects $823 million in revenue, above the $813 million consensus estimate.It maintained the company's buy rating and $750 price target.Price: $541.02, Change: $-3.90, Percent Change: -0.72%

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,167,734, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 26, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,167,734. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000087/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,228,773, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 25, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,228,773. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000086/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,108,527, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on June 22, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,108,527. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000083/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,708,786, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on June 22, 2026, sold 8,750 shares in United Therapeutics (UTHR) for $4,708,786. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000029/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,401,489, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on June 18, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,401,489. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000028/xslF345X05/primarydocument.xml

$UTHR

Showing 1-20 of 67

Track with the FINWIRES app suite

FolioX
FolioX
Track UTHR in your portfolio
WheelAI
WheelAI
Analyze UTHR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on UTHR